Real-World Impact of UGT1A1 Genotype-Guided Irinotecan Dosing on Severe Toxicity and Hospitalization: A Multicenter Study.

UGT1A1 genotype-guided irinotecan dosing to reduce severe toxicity in poor metabolizers

This multicenter real-world study evaluates the impact of UGT1A1 genotype-guided irinotecan dosing implemented in routine clinical practice since 2020. Patients carrying two dysfunctional UGT1A1 variants (poor metabolizers) receive a reduced dose to lower severe toxicity risk. Real-world results confirm a significant reduction in severe toxicity and hospitalizations.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Real-world data on UGT1A1-guided dosing were lacking — clinical trials are convincing but routine practice conditions differ. This multicenter study fills that gap and strengthens the case for systematic UGT1A1 genotyping before irinotecan chemotherapy.

Clinical impact: 3/3 · Evidence strength: 3/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 1/1 → Total: 9/10